Table 2.
Stereotactic body radiation therapy studies related to hepatocellular carcinoma, published the last five years
| Ref. | Study design | Patient (n) | Median tumor size | Dose, No. of fractions | Median follow up (range), in months | Local control |
| Cárdenes et al[77] | Prosp | 17 | 34 mL (8-95) | CP-A: 36-48 Gy/3 fr | 24 (10-42) | 100% |
| Phase I | CP-B: 40 Gy/5 fr | |||||
| Louis et al[72] | Retro | 25 | 48 mL (7-363) | 45 Gy/3 fr | 12.7 (1-24) | 95% (1 yr) |
| Kwon et al[79] | Retro | 42 | 15 mL (3-82) | 30-39 Gy/3 fr | 28.7 (8.4-49.1) | 72% (1 yr) |
| 67.5% (3 yr) | ||||||
| Seo et al[80] | Retro | 38 | 40.5 mL (11-464) | 33-57 Gy/3-4 fr | 15 (3-27) | 66% (2 yr) |
| Andolino et al[69] | Retro | 60 | 29 mL (2-12) | CP-A: 44 Gy/3 fr | 27 (2-52) | 90 (2 yr) |
| 3.2 cm (1-6.5) | CP-B: 40 Gy/5 fr | |||||
| Huang et al[81] | Retro | 36 | 4.4 cm (1.1-12) | 37 (25-48) Gy/4-5 fr | 14 (2-35) | 88% (1 yr) |
| 75% (2 yr) | ||||||
| Bae et al[82] | Retro | 35 | 131 mL (21-2189) | 45 (30-60) Gy/3-5 fr | 14 (1-44) | 69% (91 yr) |
| 51% (93 yr) | ||||||
| Bujold et al[78] | Prosp | 102 | 117 mL (1-1913) | 36 (24-54) Gy/6 fr | 31 (2-36) | 87% (1 yr) |
| Phase I/II | 7.2 cm (1.4-23.1) | |||||
| Xi et al[90] | Retro | 41 | 65 mL (± 48) | 36 (30-48) Gy/6 fr | 10 (4-25) | 95% |
| Sanuki et al[127] | Retro | 185 | 8 mL (1.5-65) | CP-A: 40 Gy/5 fr | 24 (3-80) | 91% (3 yr) |
| CP-B: 35 Gy/5 fr |
Prosp: Prospective; Retro: Retrospective; fr: Fraction; CP: Child-Pugh class of liver disease.